These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 21809353)
1. Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. Tomić TT; Gustavsson H; Wang W; Jennbacken K; Welén K; Damber JE Prostate; 2012 May; 72(7):705-12. PubMed ID: 21809353 [TBL] [Abstract][Full Text] [Related]
2. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models. Tesan T; Gustavsson H; Welén K; Damber JE BJU Int; 2008 Sep; 102(8):1034-9. PubMed ID: 18489523 [TBL] [Abstract][Full Text] [Related]
3. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153 [TBL] [Abstract][Full Text] [Related]
4. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Tang D; Nagano H; Yamamoto H; Wada H; Nakamura M; Kondo M; Ota H; Yoshioka S; Kato H; Damdinsuren B; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Wakasa K; Monden M Oncol Rep; 2006 Mar; 15(3):525-32. PubMed ID: 16465407 [TBL] [Abstract][Full Text] [Related]
5. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. Nadar SK; Blann A; Beevers DG; Lip GY J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572 [TBL] [Abstract][Full Text] [Related]
6. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients. Caine GJ; Ryan P; Lip GY; Blann AD Cancer Lett; 2007 Jun; 251(2):296-301. PubMed ID: 17240049 [TBL] [Abstract][Full Text] [Related]
7. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881 [TBL] [Abstract][Full Text] [Related]
8. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287 [TBL] [Abstract][Full Text] [Related]
9. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Strohmeyer D; Strauss F; Rössing C; Roberts C; Kaufmann O; Bartsch G; Effert P Anticancer Res; 2004; 24(3a):1797-804. PubMed ID: 15274358 [TBL] [Abstract][Full Text] [Related]
10. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844 [TBL] [Abstract][Full Text] [Related]
11. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Hata K; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Miyazaki K Gynecol Oncol; 2004 Apr; 93(1):215-22. PubMed ID: 15047239 [TBL] [Abstract][Full Text] [Related]
12. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Joseph IB; Isaacs JT Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Ochiumi T; Tanaka S; Oka S; Hiyama T; Ito M; Kitadai Y; Haruma K; Chayama K Int J Oncol; 2004 Mar; 24(3):539-47. PubMed ID: 14767538 [TBL] [Abstract][Full Text] [Related]
15. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320 [TBL] [Abstract][Full Text] [Related]
16. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Borre M; Nerstrøm B; Overgaard J Clin Cancer Res; 2000 May; 6(5):1882-90. PubMed ID: 10815911 [TBL] [Abstract][Full Text] [Related]